Pharmaxis reports Bronchitol data

Pharmaxis Ltd. (ASX:PXS) said Bronchitol mannitol missed the primary endpoint of significantly improving the absolute change in forced expiratory volume in one second (FEV1) from baseline to week 26 vs. placebo in the Phase III CF302 trial to treat cystic fibrosis (p=0.059). Bronchitol did meet the secondary endpoints of significantly improving forced vital capacity (FVC) and percent predicted FEV1 vs. placebo at week 26 (p=0.022 and p=0.024, respectively). The double-blind, international trial enrolled 318 patients. Additional data will be presented at the North American Cystic Fibrosis meeting in Baltimore in October. ...